Brokers Set Expectations for Teva Pharmaceutical Industries Limited’s Q2 2025 Earnings (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research increased their Q2 2025 earnings estimates for Teva Pharmaceutical Industries in a research report issued on Wednesday, April 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.57 per share for the quarter, up from their prior forecast of $0.56. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.53 EPS and FY2026 earnings at $2.70 EPS.

Several other research analysts have also weighed in on TEVA. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $12.00 to $19.00 in a research note on Monday, February 12th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a research note on Friday, March 8th. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price target for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. The Goldman Sachs Group increased their price target on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Up 0.6 %

Teva Pharmaceutical Industries stock opened at $12.86 on Thursday. The firm has a market cap of $14.41 billion, a PE ratio of -27.35, a P/E/G ratio of 1.58 and a beta of 1.05. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The firm’s 50 day moving average price is $13.50 and its two-hundred day moving average price is $11.25. Teva Pharmaceutical Industries has a twelve month low of $7.09 and a twelve month high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.25. The firm had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%.

Institutional Trading of Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of the company. Money Concepts Capital Corp bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $25,000. Tower Research Capital LLC TRC boosted its holdings in Teva Pharmaceutical Industries by 1,729.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock valued at $39,000 after purchasing an additional 3,580 shares during the period. US Bancorp DE boosted its holdings in Teva Pharmaceutical Industries by 36.5% in the 4th quarter. US Bancorp DE now owns 3,828 shares of the company’s stock valued at $40,000 after purchasing an additional 1,023 shares during the period. Blue Trust Inc. boosted its holdings in Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after purchasing an additional 2,180 shares during the period. Finally, Signaturefd LLC boosted its holdings in Teva Pharmaceutical Industries by 90.8% in the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock valued at $51,000 after purchasing an additional 2,394 shares during the period. 54.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP Eric Drape sold 173,261 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the sale, the vice president now directly owns 1 shares of the company’s stock, valued at approximately $13.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CAO Amir Weiss sold 31,766 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Eric Drape sold 173,261 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now directly owns 1 shares of the company’s stock, valued at $13.05. The disclosure for this sale can be found here. In the last three months, insiders sold 390,738 shares of company stock valued at $5,132,766. Company insiders own 0.62% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.